title: Open trial of intravenous immune serum globulin for chronic sinusitis in children.
abstract: BACKGROUND
  Chronic sinusitis in children is a complex clinical problem. Some patients do not improve with medical therapy and some fail surgery as well.
  
  
  OBJECTIVE
  A therapeutic trial of intravenous immune serum globulin (IVIG) was given to children whose sinus disease was recalcitrant to the usual therapeutic modalities. The objective of IVIG administration was to modulate the inflammatory process contributing to the chronicity of the sinusitis.
  
  
  METHODS
  Six patients were given a 12-month trial of monthly (400 mg/kg) IVIG infusions. Entry criteria included persistence of sinusitis after 3 months of full course antibiotics, or two episodes of sinusitis within a 3-month period while on prophylactic antibiotics. All patients had abnormal sinus CT (computerized tomography) scans at entry. Three of the six patients remained symptomatic despite prior sinus surgery. Patients with primary immune deficiencies were excluded. Each patient served as his own control based on their previous 12-month history and clinical course. Four of the 6 patients were atopic as demonstrated by prick skin testing; however, all patients had nasal eosinophilia.
  
  
  RESULTS
  Full course antibiotic use decreased in five of the six patients (183 to 84 days); correspondingly, the episodes of sinusitis decreased (average 9 to 4 per year). In addition, sinus CT scans showed significant improvement.
  
  
  CONCLUSIONS
  This preliminary open-trial of IVIG suggests its usefulness as adjunct therapy to medical management in selected patients with chronic sinus disease. The mechanism(s) by which IVIG may be helpful is probably not based on the concept of replacement therapy, but more likely as an immune or inflammatory modulating agent.
authors.affiliation: Division of Allergy and Clinical Immunology, Children's Hospital of Buffalo, State University of New York at Buffalo, 14222, USA.
authors.forename: S
authors.initials: S
authors.lastname: Ramesh
authors.forename: L
authors.initials: L
authors.lastname: Brodsky
authors.forename: E
authors.initials: E
authors.lastname: Afshani
authors.forename: M
authors.initials: M
authors.lastname: Pizzuto
authors.forename: M
authors.initials: M
authors.lastname: Ishman
authors.forename: J
authors.initials: J
authors.lastname: Helm
authors.forename: M
authors.initials: M
authors.lastname: Ballow
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D002648:Child; D002675:Child, Preschool; D002908:Chronic Disease; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D008297:Male; D011446:Prospective Studies; D012852:Sinusitis / Q000188:drug therapy*
chemical_list: D000900:Anti-Bacterial Agents; D016756:Immunoglobulins, Intravenous